Intel stock extends gains after report of possible U.S. government stake
TD Cowen has maintained its Buy rating and $282.00 price target for Alnylam Pharmaceuticals (NASDAQ: ALNY), following the company's investor event. The event focused on detailed data from the HELIOS-B study, which supports the use of vutrisiran as a first-line treatment.
The study's findings showed a statistically significant double-blind mortality benefit and the ability to measure biomarker response, which are seen as key value drivers for the company.
The analyst noted the importance of emerging guidelines that will define progressors, as these are expected to be crucial for the anticipated strong second-line usage of the treatment.
The market is looking forward to regulatory progress, with expectations for a US supplemental New Drug Application (sNDA) filing in the second half of 2024 and filings in the European Union and Japan by the end of 2024.
Alnylam Pharmaceuticals, which hosted the ESC investor event, highlighted the additive benefit of vutrisiran on top of tafamidis. The company's focus on the HELIOS-B study data is part of its strategy to bolster the drug's profile and support its use in treating patients.
The HELIOS-B study is a significant part of Alnylam's pipeline, and the positive data is a step forward in the drug's journey toward wider approval and use. With the expected regulatory filings in the US, EU, and Japan, the company is poised for potential growth in the coming years.
In other recent news, Alnylam Pharmaceuticals has been making significant strides in the pharmaceutical industry. Recent data from the company's Phase 3 HELIOS-B program presented at the European Society of Cardiology (ESC) Congress has bolstered confidence in Alnylam's AMVUTTRA (vutrisiran) treatment for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Analyst firms including H.C. Wainwright, Barclays, Citi, BMO Capital, and Stifel have maintained or upgraded their positive ratings on the company, reflecting the promising data from the study.
Alnylam's second-quarter earnings report surpassed expectations in both revenue and profit, primarily due to the growth of its TTR franchise and a milestone payment from a licensing agreement with Regeneron (NASDAQ:REGN). The company updated its 2024 revenue guidance, now expecting product revenues to reach between $1.575 billion and $1.65 billion.
In addition to its financial success, Alnylam is preparing for potential regulatory approval, with plans to submit a supplemental New Drug Application by the end of 2024. This recent development indicates the company's commitment to advancing its product pipeline, and the potential market success of vutrisiran.
These developments underscore Alnylam's commitment to delivering transformative medicines and achieving a leading biotech profile. The HELIOS-B study data plays a crucial role in demonstrating the efficacy of their product.
InvestingPro Insights
As Alnylam Pharmaceuticals (NASDAQ:ALNY) garners attention with its HELIOS-B study results, insights from InvestingPro provide a nuanced perspective on the company's financial health and market performance. Notably, Alnylam's gross profit margin impressively stands at 87.0% for the last twelve months as of Q2 2024, underscoring the company's ability to maintain profitability on its products. Despite analysts not expecting the company to be profitable this year, Alnylam's liquid assets surpass short-term obligations, indicating a strong liquidity position that could support ongoing research and development efforts.
Investors tracking the company's stock will find it interesting that Alnylam has experienced a strong return over the last three months, with a 74.6% price total return, and a significant uptick over the last six months at 72.13%. This recent performance may reflect market confidence in the company's pipeline and strategic direction. Additionally, Alnylam is trading at a high valuation multiple, with a P/E ratio of -447.12, suggesting that investors may be pricing in future growth expectations despite current non-profitability.
For those looking deeper into Alnylam's financials and market prospects, there are 12 additional InvestingPro Tips available, which could provide further guidance for investment decisions. These tips, along with a more comprehensive analysis, can be found on the InvestingPro platform at https://www.investing.com/pro/ALNY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.